Clin Infect Dis
- MCCONEGHY KW, Hur K, Dahabreh IJ, Jiang R, et al
Early Mortality After the First Dose of Coronavirus Disease 2019 Vaccination: A
Target Trial Emulation.
Clin Infect Dis. 2024 Feb 6:ciad604. doi: 10.1093.
Infect Immun
- DEJONG MA, Wolf MA, Bitzer GJ, Hall JM, et al
BECC438b TLR4 agonist supports unique immune response profiles from nasal and
muscular DTaP pertussis vaccines in murine challenge models.
Infect Immun. 2024 Feb 7:e0022323. doi: 10.1128/iai.00223.
J Infect
- AL-ABRI SS, Abuhasan MY, Albayat SSA, Bai X, et al
Meningococcal disease in the Middle East: A report from the Global Meningococcal
Initiative.
J Infect. 2024;88:71-76.
J Infect Dis
- FRIEDMAN-KLABANOFF DJ, Berry AA, Travassos MA, Shriver M, et al
Recombinant full-length Plasmodium falciparum circumsporozoite protein-based
vaccine adjuvanted with GLA-LSQ: Results of Phase 1 testing with malaria
challenge.
J Infect Dis. 2024 Feb 8:jiae062. doi: 10.1093.
- BURKE RM, Payne DC, McNeal M, Conrey SC, et al
Correlates of Rotavirus Vaccine Shedding and Seroconversion in a U.S. Cohort of
Healthy Infants.
J Infect Dis. 2024 Feb 8:jiae055. doi: 10.1093.
- HU X, Karthigeyan KP, Herbek S, Valencia SM, et al
Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad
Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than
the gB/MF59 Vaccine.
J Infect Dis. 2024 Feb 7:jiad593. doi: 10.1093.
JAMA
- HARRIS E
Africa's First Routine Malaria Vaccination Campaign Begins.
JAMA. 2024 Feb 7. doi: 10.1001/jama.2024.0170.
- NORMAN M, Magnus MC, Soderling J, Juliusson PB, et al
Neonatal Outcomes After COVID-19 Vaccination in Pregnancy.
JAMA. 2024;331:396-407.
- FELDSTEIN LR, Britton A, Grant L, Wiegand R, et al
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2
Infection in Children and Adolescents Aged 5 to 17 Years.
JAMA. 2024;331:408-416.
Lancet
- ADEPOJU P
Routine malaria vaccinations begin.
Lancet. 2024;403:423.
- DATOO MS, Dicko A, Tinto H, Ouedraogo JB, et al
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African
children: a multicentre, double-blind, randomised, phase 3 trial.
Lancet. 2024 Feb 1:S0140-6736(23)02511-4. doi: 10.1016/S0140-6736(23)02511.
- MOORTHY V, Hamel MJ, Smith PG
Malaria vaccines for children: and now there are two.
Lancet. 2024 Feb 1:S0140-6736(23)02743-5. doi: 10.1016/S0140-6736(23)02743.
N Engl J Med
- HIGGINS DM, O'Leary ST
The Risks of Normalizing Parental Vaccine Hesitancy.
N Engl J Med. 2024;390:485-487.
Pediatrics
- CARDEMIL CV, Cao Y, Posavad CM, Badell ML, et al
Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants.
Pediatrics. 2024 Feb 9:e2023064252. doi: 10.1542/peds.2023-064252.
PLoS One
- UDOAKANG AJ, Nganyewo NN, Djomkam Zune AL, Olwal CO, et al
Knowledge, attitude and perception towards COVID-19 among representative educated
sub-Saharan Africans: A cross-sectional study during the exponential phase of the
pandemic.
PLoS One. 2024;19:e0281342.
- SARMIENTO-MEDINA MI, de Amaya MP, Villamizar-Gomez L, Gonzalez-Coba AC, et al
High-risk HPV prevalence and vaccination coverage among Indigenous women in the
Colombian Amazon: Implications for cervical cancer prevention. Cross-sectional
study.
PLoS One. 2024;19:e0297579.
- LAUE T, Junge N, Leiskau C, Mutschler F, et al
Diminished measles immunity after paediatric liver transplantation-A
retrospective, single-centre, cross-sectional analysis.
PLoS One. 2024;19:e0296653.
- AGIMAS MC, Asmamaw M, Mekonen N, Mamo F, et al
Spatial pattern and associated factors of timely vaccination in Ethiopia using
EDHS-2016 data: A multilevel and spatial analysis.
PLoS One. 2024;19:e0296123.
- ASADI-POOYA AA, Nemati M, Shahisavandi M, Nemati H, et al
How does COVID-19 vaccination affect long-COVID symptoms?
PLoS One. 2024;19:e0296680.
Proc Natl Acad Sci U S A
- XU D, Powell AE, Utz A, Sanyal M, et al
Design of universal Ebola virus vaccine candidates via immunofocusing.
Proc Natl Acad Sci U S A. 2024;121:e2316960121.
Vaccine
- WELDEGEBRIEL GG, Okot C, Majingo N, Oumer NJ, et al
Resurgent rotavirus diarrhoea outbreak five years after introduction of rotavirus
vaccine in Botswana, 2018.
Vaccine. 2024 Feb 7:S0264-410X(24)00108-7. doi: 10.1016/j.vaccine.2024.
- CHEN M, Feng X, Liu J, Wang J, et al
Prokaryote-derived phosphorylated Tau epitope vaccine is immunogenic and
non-T-cell activated in the mice model.
Vaccine. 2024 Feb 7:S0264-410X(23)01517-7. doi: 10.1016/j.vaccine.2023.
- KOLANDAI K, Milne B, von Randow M, Bullen C, et al
Public opinion on global COVID-19 vaccine procurement and distribution policies:
A nationally representative survey in Aotearoa New Zealand 2022.
Vaccine. 2024 Feb 6:S0264-410X(24)00115-4. doi: 10.1016/j.vaccine.2024.
- LAMBACH P, Orenstein W, Silal S, Sbarra AN, et al
Report from the World Health Organization's immunization and vaccines related
implementation research advisory committee (IVIR-AC) meeting, Geneva, 11-13
September 2023.
Vaccine. 2024 Feb 6:S0264-410X(24)00160-9. doi: 10.1016/j.vaccine.2024.
- SOBLE A, Ko M, Gilchrist S, Malvolti S, et al
A review of potential use cases for measles-rubella, measles-mumps-rubella, and
typhoid-conjugate vaccines presented on microarray patches.
Vaccine. 2024 Feb 6:S0264-410X(23)01493-7. doi: 10.1016/j.vaccine.2023.
- KOHLI K, Jain B, Dee EC, Ho BL, et al
Addressing cultural and political drivers of vaccine hesitancy: Considerations
for the African and Asian contexts.
Vaccine. 2024 Feb 6:S0264-410X(24)00159-2. doi: 10.1016/j.vaccine.2024.
- KHAN A, Hussain I, Rhoda DA, Umer M, et al
Determinants of immunization in polio super high-risk union councils of Pakistan.
Vaccine. 2024;42:583-590.
- FERRERAS-COLINO E, Contreras M, Risalde MA, Sevilla IA, et al
Heat-inactivated mycobacteria activate the toll-like receptor 2 and 4 pathways in
the zebrafish model of tuberculosis.
Vaccine. 2024;42:403-409.
- FILIPAS DK, Labban M, Beatrici E, Stone BV, et al
Exploring preventive care practices among unvaccinated individuals in the United
States during the COVID-19 pandemic.
Vaccine. 2024;42:441-447.
- MIYAMOTO S, Suzuki T
Infection-mediated immune response in SARS-CoV-2 breakthrough infection and
implications for next-generation COVID-19 vaccine development.
Vaccine. 2024 Feb 2:S0264-410X(24)00112-9. doi: 10.1016/j.vaccine.2024.
- WANG ZJ, Zhang RR, Wu M, Zhao H, et al
Development of a live-attenuated chimeric vaccine against the emerging Usutu
virus.
Vaccine. 2024 Feb 2:S0264-410X(24)00098-7. doi: 10.1016/j.vaccine.2024.
- LI D, Han M, Cao Y, Du J, et al
Protective effect against toxoplasmosis in BALB/C mice vaccinated with
recombinant Toxoplasma gondii CDPK3, GRA35, and ROP46 protein cocktail vaccine.
Vaccine. 2024 Feb 2:S0264-410X(24)00062-8. doi: 10.1016/j.vaccine.2024.
- KURIYAMA K, Murakami K, Sugiura K, Sakui S, et al
One-year follow-up of the immunogenicity and safety of a primary series of the
NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase
I/II randomized controlled trial.
Vaccine. 2024 Feb 2:S0264-410X(24)00068-9. doi: 10.1016/j.vaccine.2024.
- HWANG YH, Byeon Y, Ahn SH, Kim MY, et al
Live attenuated smallpox vaccine candidate (KVAC103) efficiently induces
protective immune responses in mice.
Vaccine. 2024 Feb 2:S0264-410X(24)00076-8. doi: 10.1016/j.vaccine.2024.
- HOUY N, Flaig J
Value of information dynamics in Disease X vaccine clinical trials.
Vaccine. 2024 Feb 3:S0264-410X(24)00075-6. doi: 10.1016/j.vaccine.2024.
- KIM NE, Kim MJ, Park BJ, Kwon JW, et al
A DNA vaccine against GII.4 human norovirus VP1 induces blocking antibody
production and T cell responses.
Vaccine. 2024 Feb 5:S0264-410X(24)00114-2. doi: 10.1016/j.vaccine.2024.
- MAEDA M, Murata F, Fukuda H
The age-specific impact of COVID-19 vaccination on medical expenditures and
hospitalization duration after breakthrough infection: The Vaccine Effectiveness,
Networking, and Universal Safety (VENUS) Study.
Vaccine. 2024 Feb 5:S0264-410X(24)00106-3. doi: 10.1016/j.vaccine.2024.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016